trialist

Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.

Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.

Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.

NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer.

Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.

Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.

Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival.

Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers.

Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose.

Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.

New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.

Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.

Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.

Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level.

Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer.

Canadian surgeon who led ORATOR, the first randomised trial to compare robotic surgery with radiotherapy for early throat cancer, which found swallowing was slightly better after radiotherapy.

Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed.

Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer.

Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma.

Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma.

London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises.

Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer.

Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia.

Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.

London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma.

British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide.

Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it.

Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away.

Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.

Marseille oncologist who led REGOBONE, the trial that showed regorafenib delays progression in metastatic osteosarcoma and other bone sarcomas.

Italian haematologist who led APL0406, the trial that showed acute promyelocytic leukaemia can be cured with all-trans retinoic acid and arsenic trioxide alone, without chemotherapy.

Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.

Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease.

Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer.

London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.

Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug.

Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy.

Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.

Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.

Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.

German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer.

Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST.

Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy.

Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer.

Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer.

Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia.

Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma.

Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours.

Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.

Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma.

Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials.

Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer.

Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.

Florida leukaemia doctor who led the phase 3 trial of CPX-351, the liposomal form of daunorubicin and cytarabine that lengthened survival for older people with secondary acute myeloid leukaemia.

Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.

Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib.

German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival.

Nice oncologist who led TPExtreme, the GORTEC trial that showed the shorter TPEx regimen is a reasonable alternative to EXTREME for recurrent or metastatic head and neck cancer.

Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.

Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease.